Dan,
Our discussion shows how important well-defined terms are. Unfortunately, the IVDR does not have any for this situation. If anyone asks anything about "LDT" in the IVDR context, the first thing to do is to understand what this persons means by "LDT".
In this discussion, you equal "LDT" with devices meeting art. 5.5 requirements. Fine. You have the right to do so. However, this is a definition which is not widely recognized. For example, I refer to the fact that I know many US companies, stating that they have LDT. Yet, they are commercial companies and not health institutions. They do not meet the art. 5 conditions and will have to go through the full CE certification, including PMPF. Furthermore, they are not based in the (European) Union whereas art. 5.5 clearly states that the exemption only applies to devices manufactured and used in the Union. Another reason for North-American laboratories to prepare for CE certification.
I would not call ASR off-topic. Many labs in Europe use reagents without CE mark, usually labeled RUO (another undefined term in the EU). There is a lot of discussion in Europe on how the IVDR affect this practice. The same for the use of CE marked IVD outside the intended purpose. It is an on-going discussion , but the general belief is that these labs will have to comply with the IVDR, either with the art. 5.5 exemption or not, as the case may be. To be continued.
I must say that I do not understand why art. 5.4 is not relevant because "
This is the case where the laboratory purchases and conducts a test from an external IVD manufacturer". It says exactly the opposite: "Devices that are manufactured and used within health institutions, with the exception of devices for performance studies, shall be considered as having been put into service." I don't understand how you come to that conclusion.
.
We can probably go on for a few more rounds, but I will leave at this. I think Maham as plenty of things to think about. I find this discussion quite interesting. I wish we could continue it over a glass of beer :-)
Best regards,
Dirk
------------------------------
Dirk Stynen PhD
President
QARAD
Belgium
dirk.stynen@qarad.comhttps://www.qarad.com/e-labeling-eifu------------------------------
Original Message:
Sent: 08-May-2021 17:00
From: Dan O'Leary
Subject: EU IVDR: PMPF for LDTs?
Dirk,
It is a simple as I had stated. The complexity arises from off-topic cases such as Analyte Specific Reagents.
The initial question, paraphrased, is "Is PMPF required for an LDT under the IVDR"? I responded "No because", and cited IVDR Article 5(5).
The term LDT, Laboratory Developed Test, is in common use in the US and other parts of the world. In the good old days, we called them home brew.
The US device regulations do not define the term LDT. Although LDTs are, in general, medical devices, and are in particular in-vitro diagnostic devices, FDA, through a policy of enforcement discretion, does not regulate them.
There is an FDA document, The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies, with a good working definition of an LDT. "Laboratory developed tests (LDTs) are the subset of IVDs intended for clinical use that are designed, manufactured, and used in a single laboratory, as opposed to other IVDs made by a conventional manufacturer and used by many laboratories".
In the US, LDTs fall under the laboratory regulations which cover conducting the tests, not their design and manufacture.
In contrast, the IVDR regulates the design and manufacture of LDTs, but not conducting the tests.
The regulation is in IVDR Art. 5(5). The head of the section says that the requirements of the IVDR do not apply, expect for Annex I, to devices manufactured and used only within health institutions established in the Union, provided the laboratory meets all of the conditions in Art. 5(5)(a) to Art. 5(5)(i). The laboratory must be part of a health institution which, following Art. 2(29) "means an organization the primary purpose of which is the care or treatment of patients or the promotion of public health".
Neither Annex I nor any of the other conditions require Annex III PMS, Annex XIII Performance Evaluation, Annex XIII Performance Studies, nor Annex III Poet-Market Performance Follow-up.
Also Art. 5(4) is not relevant. This is the case where the laboratory purchases and conducts a test from an external IVD manufacturer.
Conclusion: PMPF is not required for an LDT under the IVDR
Regards,
Dan
------------------------------
Dan O'Leary CQA, CQE
Swanzey NH
United States
Original Message:
Sent: 08-May-2021 10:40
From: Dirk Stynen
Subject: EU IVDR: PMPF for LDTs?
Dear Dan,
It is a bit more complicated than that. I kindly suggest that you read Richard's and my comments.
Best,
Dirk
------------------------------
Dirk Stynen PhD
President
QARAD
Belgium
dirk.stynen@qarad.com
https://www.qarad.com/e-labeling-eifu
Original Message:
Sent: 08-May-2021 10:16
From: Dan O'Leary
Subject: EU IVDR: PMPF for LDTs?
LDTs come under the IVDR Article 5(5) which says, "With the exception of the relevant general safety and performance requirements set out in Annex I, the requirements of this Regulation shall not apply to devices manufactured and used only within health institutions established in the Union, provided that all of the following conditions are met …"
Because the IVDR in general, except Annex I, doesn't apply, then PMPF in particular does not apply.
------------------------------
Dan O'Leary CQA, CQE
Swanzey NH
United States
Original Message:
Sent: 07-May-2021 17:06
From: Maham Ansari
Subject: EU IVDR: PMPF for LDTs?
Hello Regulatory Community
I have a question about Post-Market Performance Follow-Up on Laboratory Developed Tests (LDT). If you have a test that was developed at a single laboratory site, is meant to be used ONLY at that site, with no intention to market or distribute it commercially, could you provide a justification to be exempted from the PMPF? It seems like most of the PMPF requirements outlined in the IVDR don't apply. Any light you could shed on this would be greatly appreciated.
Thank you.
------------------------------
Maham Ansari MS, RAC
Director, IVD Regulatory & Quality
Canada
------------------------------